U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Public Workshop: Understanding Priorities for the Development of Digital Health Technologies to Support Clinical Trials for Drug Development and Review - 03/28/2023
  1. Drugs

Public | Virtual

Event Title
Public Workshop: Understanding Priorities for the Development of Digital Health Technologies to Support Clinical Trials for Drug Development and Review
March 28 - 29, 2023


Date:
March 28 - 29, 2023
Day1:
Tue, Mar 28 1:00 p.m. - 04:15 p.m. ET
Day2:
Wed, Mar 29 1:00 p.m. - 04:45 p.m. ET

Date

March 28-29, 2023 

Time

  • March 28, 2023, 1:00 PM – 4:15 PM ET 
  • March 29, 2023, 1:00 PM – 4:45 PM ET 

Organized By

Office of Medical Policy

Attend 

Register for this event 

Summary 

FDA and the Duke-Robert J. Margolis, MD Center for Health Policy will host the virtual public workshop “Understanding Priorities for the Development of Digital Health Technologies to Support Clinical Trials for Drug Development and Review” on March 28, 2023, 1:00 PM – 4:15 PM ET and March 29, 2023, 1:00 PM – 4:45 PM ET. The purpose of the public workshop is to understand the priorities for the development of Digital Health Technologies (DHTs) to support clinical drug trials, including accessibility, diversity, and clinical outcomes measures using DHTs.   

FDA plans to discuss priorities and challenges for the development of DHTs to support clinical drug trials including:  

  • improving participant access, increasing diversity, and facilitating engagement through remote trial-related measurements; 
  • understanding patient and industry perspectives;   
  • understanding opportunities for remote data acquisition directly from trial participants; and 
  • using DHTs to capture clinical outcomes measures.   

Contact 

Dianne.Paraoan@fda.hhs.gov | 301-796-3161 

Office of Medical Policy, Center for Drug Evaluation and Research 

Back to Top